Bank Pictet & Cie Europe AG Sells 42,242 Shares of Merck & Co., Inc. $MRK

Key Points

• Bank Pictet & Cie Europe AG reduced its Merck stake by 18.2%, selling 42,242 shares during the third quarter and retaining 190,354 shares valued at approximately $27.66 million. Institutional investors collectively own 76.07% of MRK.
• Merck shares opened at $148.19, up 3.2%, while analysts maintain a “Moderate Buy” consensus with an average price target of $151.92. The company recently reported quarterly revenue of $16.61 billion and declared an annualized dividend of $3.40 per share.
• Investors are weighing Merck’s promising newer cancer treatments against Keytruda patent-cliff risk. Recent insider selling and reported ETF selling add near-term pressure, although analysts largely remain positive on the stock.

Bank Pictet & Cie Europe AG lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 18.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 190,354 shares of the company's stock after selling 42,242 shares during the period. Bank Pictet & Cie Europe AG's holdings in Merck & Co., Inc. were worth $27,660,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Horizons Wealth Management bought a new position in Merck & Co., Inc. during the 3rd quarter worth $30,000. Bullseye Investment Management LLC bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at about $27,000. Graney & King LLC grew its position in shares of Merck & Co., Inc. by 400.0% in the 2nd quarter. Graney & King LLC now owns 250 shares of the company's stock valued at $32,000 after buying an additional 200 shares during the last quarter. Montgomery Financial Services LLC bought a new position in shares of Merck & Co., Inc. during the second quarter worth about $41,000. Finally, Evergreen Advisors LLC bought a new position in shares of Merck & Co., Inc. during the first quarter worth about $43,000. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Stock Up 3.2%

Shares of NYSE:MRK opened at $148.19 on Wednesday. Merck & Co., Inc. has a 1 year low of $82.01 and a 1 year high of $156.92. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The business's 50-day moving average is $146.22 and its 200-day moving average is $129.67. The company has a market capitalization of $365.62 billion, a price-to-earnings ratio of 118.55, a P/E/G ratio of 6.64 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The firm's revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts predict that Merck & Co., Inc. will post 2.66 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio is presently 272.00%.

Analyst Upgrades and Downgrades

MRK has been the topic of a number of recent analyst reports. UBS Group lifted their price objective on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a "buy" rating in a research note on Thursday, August 20th. CICC Research began coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 target price for the company. Jefferies Financial Group raised their price target on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a "buy" rating in a report on Thursday, August 20th. Cantor Fitzgerald raised their price target on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a "neutral" rating in a report on Thursday, October 8th. Finally, Morgan Stanley dropped their price target on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an "overweight" rating on the stock in a research report on Wednesday, October 7th. Seventeen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $151.92.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s newer cancer treatments and encouraging Phase 3 melanoma results may help broaden its oncology franchise and reduce reliance on Keytruda. Investors are assessing whether these products can become meaningful growth drivers before Keytruda faces patent-related competition. How Investors Are Reacting To Merck Phase 3 Melanoma Results
• Positive Sentiment: The company’s diversified drug portfolio, research investments and dividend—approximately a 2.4% yield—provide support for investors seeking income while waiting for newer therapies to offset future Keytruda pressure. Merck also previously raised its 2026 sales outlook. Merck’s 2.4% Dividend Yield
• Neutral Sentiment: Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion in cash, including $20 per American depositary share. The deal could strengthen the German company’s pipeline, but Merck KGaA is a separate company from U.S.-listed Merck & Co. (MRK), so the transaction does not directly affect MRK’s earnings or stock.
• Negative Sentiment: Keytruda’s concentration creates a significant patent-cliff risk. New treatments must scale rapidly enough to replace a large portion of sales and profits when competition arrives, adding uncertainty to Merck’s valuation and long-term growth outlook. Merck Has New Cancer Treatments
• Negative Sentiment: Exchange-traded funds were reported as net sellers of MRK, indicating some short-term institutional or systematic selling pressure despite the company’s underlying growth initiatives. ETFs Are Net Sellers of Merck

Insider Activity

In related news, EVP Jennifer Zachary sold 80,315 shares of the business's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares in the company, valued at $6,073,631.14. The trade was a 63.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Chirfi Guindo sold 15,000 shares of the business's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the transaction, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. The trade was a 24.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 228,238 shares of company stock worth $29,977,783. Company insiders own 0.17% of the company's stock.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.